Gene expression profile of different cell types in the tumor microenvironment of MOC1 tumors that responded or not to treatment with Smyd3 ASOs and anti-PD-1 combination therapy.
We used scRNA-seq to assess the transcriptomic differences in the different cell types of the TME of MOC1 tumors that responded or not to Smyd3 ASOs and anti-PD-1 combination therapy. Overall design: MOC1 tumors were implanted in the flank of C57BL/6 mice and were treated with the combination of Smyd3 or control ASOs plus anti-PD-1 for 29 days. 2 responder and 2 non-responder tumors to the Smyd3 ASO plus anti-PD-1 were surgically resected, digested into single-cell suspensions and scRNA-seq was conducted.